Barbara Duncan
Directeur/Membre du Conseil chez HALOZYME THERAPEUTICS, INC.
Fortune : 934 606 $ au 30/06/2024
Profil
Barbara Gayle Duncan is currently an Independent Director at Halozyme Therapeutics, Inc., Atea Pharmaceuticals, Inc., Ovid Therapeutics, Inc., Director at Halozyme, Inc., and Non-Executive Director at Versanis Bio, Inc. She previously served as Chairman at Fusion Pharmaceuticals, Inc., Independent Director at Immunomedics, Inc., Chief Executive & Financial Officer, Director at DOV Pharmaceutical, Inc., Director at Edgemont Pharmaceuticals LLC, Director-Corporate Finance at SBC Warburg Dillon Read Corporate Finance AG, Director at Innoviva, Inc., Independent Director at Aevi Genomic Medicine, Inc., Non-Executive Director at Adaptimmune Ltd., Independent Director at Jounce Therapeutics, Inc., Independent Director at ObsEva SA, Independent Non-Executive Director at Adaptimmune Therapeutics Plc, Vice President-Corporate Finance Division at Lehman Brothers, Inc., Principal at PepsiCo, Inc., and Chief Financial Officer, Secretary & Treasurer at Intercept Pharmaceuticals, Inc. She also worked as a Principal at Deloitte & Touche LLP.
Ms. Duncan received her undergraduate degree from Louisiana State University in 1985 and her MBA from The Wharton School of the University of Pennsylvania in 1994.
Détentions connues dans des sociétés publiques
| Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
|---|---|---|---|---|
| 25/04/2024 | 15 754 ( 0,01% ) | 824 879 $ | 30/06/2024 | |
| 21/06/2024 | 33 150 ( 0,04% ) | 109 727 $ | 30/06/2024 | |
OVID THERAPEUTICS INC.
-.--% | 09/04/2024 | 0 ( -.--% ) | - $ | 30/06/2024 |
Postes actifs de Barbara Duncan
| Sociétés | Poste | Début |
|---|---|---|
| OVID THERAPEUTICS INC. | Directeur/Membre du Conseil | 14/06/2017 |
| ATEA PHARMACEUTICALS, INC. | Directeur/Membre du Conseil | 01/10/2020 |
| HALOZYME THERAPEUTICS, INC. | Directeur/Membre du Conseil | 03/02/2023 |
Versanis Bio, Inc.
 Versanis Bio, Inc. BiotechnologyHealth Technology Part of Eli Lilly & Co., Versanis Bio, Inc. is a clinical-stage biopharmaceutical company. The company is based in New York, NY. The company was founded by Lloyd Klickstein. Mark E. Pruzanski has been the CEO of the company since 2021. Versanis Bio was acquired by Eli Lilly & Co. on August 14, 2023 for $1,925 million. | Directeur/Membre du Conseil | 20/07/2022 |
Halozyme, Inc.
 Halozyme, Inc. BiotechnologyHealth Technology Part of Halozyme Therapeutics, Inc., Halozyme, Inc. is a company based in San Diego, CA. | Directeur/Membre du Conseil | 01/02/2023 |
Anciens postes connus de Barbara Duncan
| Sociétés | Poste | Fin |
|---|---|---|
| FUSN PHAR | Président | 04/06/2024 |
| ADAPTIMMUNE THERAPEUTICS PLC | Directeur/Membre du Conseil | 01/06/2023 |
| JOUNCE THERAPEUTICS, INC. | Directeur/Membre du Conseil | 03/05/2023 |
| OBSEVA SA | Directeur/Membre du Conseil | 28/05/2021 |
| ░░░░░░░░░░░░░ ░░░░ | ░░░░░░░░░░░░░░░░ ░░ ░░░░░░░ | ░░░░░░░░░░ |
Formation de Barbara Duncan
| Louisiana State University | Undergraduate Degree |
| The Wharton School of the University of Pennsylvania | Masters Business Admin |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 8 |
|---|---|
| PEPSICO, INC. | Consumer Non-Durables |
| HALOZYME THERAPEUTICS, INC. | Health Technology |
| INTERCEPT PHARMACEUTICALS, INC. | Health Technology |
| ATEA PHARMACEUTICALS, INC. | Health Technology |
| OVID THERAPEUTICS INC. | Health Technology |
| INNOVIVA, INC. | Health Technology |
| OBSEVA SA | Health Technology |
| ADAPTIMMUNE THERAPEUTICS PLC | Health Technology |
| Entreprise privées | 12 |
|---|---|
Immunomedics, Inc.
 Immunomedics, Inc. BiotechnologyHealth Technology Immunomedics, Inc. researching, developing, manufacturing, and marketing biopharmaceutical products. It focuses on monoclonal antibody-based products for the targeted treatment of cancer. The company was founded by David M. Goldenberg in July 1982 and is headquartered in Morris Plains, NJ. | Health Technology |
Lehman Brothers, Inc.
 Lehman Brothers, Inc. Investment Banks/BrokersFinance A subsidiary of Lehman Brothers Holdings, Inc., Lehman Brothers, Inc. is a broker/dealer headquartered in New York City. They provide global equity and fixed research. The equity research department covers more than 100 sectors. They use a fundamental, quantitative, strategic and tactical research approach. In addition to these Lehman has also developed special products, such as 10 uncommon values and 10 uncommon eurovalues. | Finance |
DOV Pharmaceutical, Inc.
 DOV Pharmaceutical, Inc. Miscellaneous Commercial ServicesCommercial Services DOV Pharmaceutical, Inc. discovers and develops novel drugs. It focuses on the development of novel product candidates for disorders of the central nervous system, or CNS. It have drug development programs that are at the preclinical, Phase I and Phase II clinical stages, including DOV 21,947 (in a Phase II clinical trial for depression), DOV 102,677 (which has completed a Phase I clinical trial) and a preclinical discovery program in reuptake inhibitors and GABA modulators. The company was founded by Arnold S. Lippa in May, 1995 and is headquartered in Somerset, NJ. | Commercial Services |
Edgemont Pharmaceuticals LLC
 Edgemont Pharmaceuticals LLC Pharmaceuticals: MajorHealth Technology Edgemont Pharmaceuticals LLC develops and provides products for psychiatric disorders. The company was founded by Douglas A. Saltel in 2008 and is headquartered in Austin, TX. | Health Technology |
Deloitte & Touche LLP
 Deloitte & Touche LLP Miscellaneous Commercial ServicesCommercial Services Deloitte & Touche LLP engages in the provision of audit, advisory, financial advisory, tax, and consulting services. The company was founded on March 7, 1995 and is headquartered in New York, NY. | Commercial Services |
| SBC Warburg Dillon Read Corporate Finance AG | Finance |
Aevi Genomic Medicine, Inc.
 Aevi Genomic Medicine, Inc. Pharmaceuticals: MajorHealth Technology Aevi Genomic Medicine, Inc. is a clinical stage biopharmaceutical company, which engaged in the discovery of treatments for rare and orphan diseases. Its research and development efforts leverage an internal genomics platform and an ongoing collaboration with the Center for Applied Genomics (CAG) at The Children's Hospital of Philadelphia (CHOP). The company was founded by Andrew Leonard Pearlman on January 27, 2000 and is headquartered in Wayne, PA. | Health Technology |
Adaptimmune Ltd.
 Adaptimmune Ltd. Medical/Nursing ServicesHealth Services Adaptimmune Ltd. develops T cell therapies to treat cancer, human immunodeficiency virus, and infectious diseases. It utilizes the T cell to target and destroy cancerous and infected cells by using affinity T cell receptor proteins as a means of strengthening patient T cell responses. The company was founded by Bent K. Jakobsen, James Julian Noble and Helena Katrina Tayton-Martin in 2008 and is headquartered in Oxford, the United Kingdom. | Health Services |
Jounce Therapeutics, Inc.
 Jounce Therapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services Jounce Therapeutics, Inc. is a clinical stage immunotherapy company, which engages in developing treatments for cancer. It also provides novel cancer immunotherapies to attack tumors. The company was founded by Louis M. Weiner, Drew M. Pardoll, Thomas F. Gajewski, James P. Allison, Robert Schreiber, and Padmanee Sharma in 2013 and is headquartered in Cambridge, MA. | Commercial Services |
Fusion Pharmaceuticals, Inc.
 Fusion Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Fusion Pharmaceuticals, Inc. operates as a biopharmaceutical company. It develops GMP manufacturing of radiopharmaceuticals for the diagnosis and treatment of disease. The company was founded by John Vaillant in 2014 and is headquartered in Hamilton, Canada. | Health Technology |
Versanis Bio, Inc.
Versanis Bio, Inc. BiotechnologyHealth Technology Part of Eli Lilly & Co., Versanis Bio, Inc. is a clinical-stage biopharmaceutical company. The company is based in New York, NY. The company was founded by Lloyd Klickstein. Mark E. Pruzanski has been the CEO of the company since 2021. Versanis Bio was acquired by Eli Lilly & Co. on August 14, 2023 for $1,925 million. | Health Technology |
Halozyme, Inc.
Halozyme, Inc. BiotechnologyHealth Technology Part of Halozyme Therapeutics, Inc., Halozyme, Inc. is a company based in San Diego, CA. | Health Technology |
